Active, not recruitingEarly Phase 1NCT05053750
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Studying Malignant tumor of fallopian tubes
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Shannon Westin, MDM.D. Anderson Cancer Center
- Intervention
- Paclitaxel/Bev (control)(drug)
- Enrollment
- 14 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
Gateway for Cancer Research · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05053750 on ClinicalTrials.gov